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High levels of plasma marine n-3 fatty acids (n-3FAs) are associated with improved patient
and graft survival in renal transplant recipients (RTRs). The aim of this study was to evaluate
the utility of a new food frequency questionnaire (FFQ) to estimate marine n-3FA consump-
tion in future epidemiological research.
Methods
We developed an FFQ with a simple design of 10 questions to assess intake of marine
sources of n-3FAs. RTRs included in the recent ORENTRA trial (n = 132) completed the
study FFQ at the baseline visit eight weeks after engraftment and at the end of study visit
one year post-transplant. We measured the reference biomarker plasma phospholipid (PL)
marine n-3FA levels by gas chromatography at the same time points to evaluate association
and degree of agreement between FFQ based marine n-3FA consumption estimates and
the biomarker.
Results
The median plasma PL marine n-3FA level was 6.0 weight percentage (wt)% (interquartile
range [IQR] 4.7 to 7.3) at baseline and 6.3 wt% (IQR 4.8 to 7.4) at end of study. Median FFQ
based marine n-3FA consumption estimates were 22.8 g/month (IQR 13.0 to 34.0) at base-
line and 20.3 g/month (IQR 14.5 to 32.3) at end of study. FFQ based marine n-3FA con-
sumption estimates showed a moderate correlation with plasma PL marine n-3FA levels at
baseline (Spearman’s correlation coefficient rs = 0.43, p<0.001) and a stronger correlation
at end of study (rs = 0.62, p<0.001). Bland Altman plots showed a reasonable degree of
agreement between the two methods at both time points.
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Conclusions
Marine n-3FA consumption estimates based on the FFQ showed a moderate correlation
with the reference biomarker plasma PL marine n-3FA levels. The FFQ might be useful in
epidemiological studies where resources are limited.
Introduction
Marine n-3 fatty acid (n-3FA) consumption may benefit cardiovascular health and renal func-
tion following renal transplantation [1, 2]. Previous clinical trials in renal transplant recipients
(RTRs) report lower triglyceride levels, higher high-density lipoprotein cholesterol levels and
lower diastolic blood pressure after marine n-3FA supplementation [1]. A large cohort study
in Norwegian RTRs showed that high plasma phospholipid (PL) n-3FA levels were associated
with improved patient and graft survival [3, 4]. Antifibrotic and renoprotective effects of long-
term high-dose marine n-3FA supplementation have also been shown for other cardiovascular
high-risk populations like myocardial infarction survivors [5, 6]. The recent “Omega-3 fatty
acids in Renal Transplantation (ORENTRA)” trial performed in Norwegian RTRs found lower
levels of inflammatory biomarkers, less development of renal graft fibrosis and improvement
of endothelial function, as well as reduced triglyceride levels after 44 weeks of high-dose n-3FA
supplementation [2].
Observational studies and randomized clinical trials (RCTs) studying the influence of
marine n-3FA intake on cardiovascular health report conflicting results [7–14]. But a recent
meta-analysis, which included three recent large RCTs [15–17], concluded that marine n-3FA
supplementation was associated with a lower risk of cardiovascular events and death [18]. In
renal transplantation, further studies are warranted to evaluate to what extent marine n-3FA
consumption may improve patient and graft survival.
The major marine n-3FAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
are found in fish and other seafood. Plasma PL levels of EPA and DHA can be measured by
fatty acid analysis and are considered valid and reliable measures of marine n-3FA consump-
tion [19]. However, fatty acid analysis is more expensive and time-consuming to apply than a
food frequency questionnaire (FFQ). Hence, replacing fatty acid analyses with an FFQ focused
on marine n-3FA consumption seems attractive in epidemiological research, provided that the
FFQ values show a high degree of agreement and association with the reference biomarker.
The main objective of this study was therefore to evaluate the utility of a new FFQ focused
on marine n-3FA consumption, using plasma PL marine n-3FA level as the reference
biomarker.
Materials and methods
Study participants and design
The study cohort consisted of 132 adult Norwegian RTRs included in the ORENTRA trial [2],
who were randomized to receive daily supplementation of either 2.6 g of marine n-3FAs (EPA
plus DHA) or 3 g of extra virgin olive oil (control oil) for 44 weeks. All patients gave written
informed consent for participation in the trial, which also comprised the study FFQ and fatty
acid analysis. The study was approved by the Regional Committees for Medical and Health
Research Ethics in Norway and was performed in accordance with the Declaration of Helsinki
(Clinical.Trials.gov identifier NCT01744067). FFQ and fatty acid analysis were performed
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eight weeks post-engraftment (baseline visit) and one year after transplantation (end of study
visit). Patients were treated with standard triple maintenance immunosuppressive regimen
consisting of prednisolone, mycophenolate and tacrolimus. Blood samples were drawn in a
fasting state in the morning at the baseline and end of study visits. Gas chromatography was
used to determine individual fatty acid levels in plasma PLs, quantified as weight percentage
(wt%) of total plasma PL fatty acids. We defined marine n-3FA level as the sum of EPA and
DHA. The study was performed at Oslo University Hospital during 2012–2015. Details regard-
ing recruitment of patients, fatty acid analysis and the study FFQ are provided in the S1 File.
For the ORENTRA trial, we developed a specific FFQ with a simple design of 10 multiple-
choice questions (Fig 1), focusing on food items containing marine sources of n-3FA that are
typically found in a Nordic diet [20].
We used three different approaches to estimate marine n-3FA consumption at baseline and
end of study based on the FFQ recordings:
1. Marine n-3FA consumption estimates, calculated by combining data from the FFQ with
known content of EPA and DHA in fish and other seafoods [21], assuming a standard por-
tion size for a Norwegian population (S1 File, S2 Fig).
2. Marine n-3FA consumption estimates calculated as in approach 1 using only data on fatty
fish intake for lunch and dinner (S3 Fig).
3. Number of fish servings per month (S4 Fig).
Statistical analysis
We used correlation analysis (Spearman’s correlation coefficient [rs]) and multivariate regres-
sion analysis (data presented as standardized regression coefficients [Std. β-coeff.]) to study
associations between FFQ based marine n-3FA consumption estimates and plasma PL marine
n-3FA levels. Data obtained by the reference biomarker and the study FFQ were standardized
using z-statistics to produce data for both methods on the same scale. This allowed for a more
meaningful visual presentation (scatter plots) and made it possible to analyze degree of agree-
ment using Bland Altman plots and one-sample t-test. Since the study drug used in the OREN-
TRA trial was high-dose marine n-3FA supplementation, we excluded patients in the
intervention group when performing statistical analysis of data from the end of study visit.
Two patients belonging to the control group did not meet at the end of study visit (n = 66 at
baseline, n = 64 at end of study visit). Patient characteristics at baseline grouped according to
plasma PL marine n-3FA tertiles were evaluated with analysis of variance for continuous data
and Mantel-Haenszel linear-by-linear-trend for categorical data. A two-sided p-value
of< 0.05 was considered statistically significant. We used SPSS1 version 25.0 (IBM, New
York, NY, US) for statistical analyses.
Results
Patient characteristics for the study cohort have previously been published in detail [2].
Selected variables, grouped according to plasma PL n-3FA tertiles at baseline eight weeks
post-transplant, are presented in Table 1. Patients in the upper tertile were older and less often
current smokers. Supplementation with cod liver oil was used by 28% of patients in the upper
tertile compared with 9% in the lower. Median plasma PL n-3FA levels were 6.0 wt% (inter-
quartile range [IQR] 4.7 to 7.3, n = 132) at the baseline visit and 6.3 wt% (IQR 4.8 to 7.4,
n = 64) at the end of study visit. Median FFQ based marine n-3FA consumption estimates
were 22.8 g/month (IQR 13.0 to 34.0, n = 132) at baseline and 20.3 g/month (IQR 14.5 to 32.3,
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Fig 1. Study food frequency questionnaire focusing on food items containing marine n-3 polyunsaturated fatty acids (English
version). The study subjects responded to the question “During a typical month, how often do you eat these food items?” using one of
six response alternatives for each of the ten food item categories.
https://doi.org/10.1371/journal.pone.0244089.g001
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n = 64) at end of study. Marine n-3FA consumption remained stable during follow-up in the
control group with a median increase of plasma PL marine n-3FA level of 0.1 wt% (IQR -0.8 to
1.0) and change in FFQ based marine n-3FA consumption estimates of -1.0 g/month (IQR
-9.4 to 6.3).
At baseline, moderate correlations were found between FFQ based marine n-3FA con-
sumption estimates and the reference biomarker plasma PL marine n-3FA levels (approach 1,
rs = 0.43, p<0.001, n = 132, Fig 2). A reasonable degree of agreement between the study FFQ
estimates and the reference biomarker was shown in a Bland Altman plot (Fig 3) and signifi-
cant bias was ruled out by a one-sample t-test (t = 0.04, p = 0.96). Two groups of outlier obser-
vations were identified. One group consisted of patients reporting high intake of marine n-
3FAs but had average plasma PL marine n-3 FA levels. Another group with high or very high
plasma PL marine n-3FA levels had average marine n-3FA consumption according to the
study FFQ.
Correlations between FFQ based marine n-3FA consumption estimates and plasma PL
marine n-3FA levels were stronger at the end of study (rs = 0.60, p<0.001, n = 64, Fig 4) than
at baseline. One-sample t-test (t = 0.06, p = 0.95) and a Bland Altman plot confirmed an
acceptable degree of agreement between the two methods at this time point (Fig 5).
Table 1. Patient characteristics at baseline eight weeks after renal transplantation according to plasma phospholipid marine n-3 fatty acid tertiles.
Variables All patients Plasma PL marine n-3FA level, wt% p (trend)
�5.1 5.2–6.9 �7.0
Number of patients 132 44 44 44
FFQ based marine fatty acid consumption estimate, g/month 26.0 (16.6) 19.8 (15.0) 25.4 (17.5) 33.1 (14.7) 0.001
Number of servings of fish / month 19.9 (15.6) 13.3 (13.8) 16.2 (13.4) 26.9 (16.8) 0.12
Marine n-3FA supplements, % 14.5 9.1 6.8 27.9 0.01
Recipient age, years 53.4 (13.8) 45.7 (12.6) 55.6 (13.6) 59.1 (12.0) <0.001
Recipient gender (Female), % 25.8 27.3 25.0 25.6 0.86
Ethnicity, White, % 92.4 93.2 86.0 97.7 0.39
Body mass index, kg/m2 26.0 (3.9) 25.2 (4.0) 25.9 (3.8) 26.8 (3.7) 0.16
Educational level, %
>3 years at University 29.8 27.3 27.3 34.9
1–3 years at University 7.6 6.8 6.8 9.3
Secondary school 35.1 40.9 36.4 27.9
Primary school 27.5 25.0 29.5 27.9 0.56
Physical exercise, %
High intensity� twice per week 42.1 51.2 36.4 39.0
High intensity once per week 9.5 2.4 11.4 14.6
Low intensity� twice per week 34.9 36.6 36.4 31.7
Low intensity once per week 7.1 9.8 9.1 2.4
None 6.3 0.0 6.8 12.2 0.29
Smoking habits, %
Daily smoker 12.7 19.5 11.4 7.3
Non-daily smoker 3.2 7.3 0.0 2.4
Former heavy smoker 7.1 7.3 4.5 9.8
Former light smoker 35.7 34.1 43.2 29.3
Life-long non-smoker 41.3 31.7 40.9 51.2 0.03
Patient characteristics are presented as percentage for categorical data and mean value (standard deviation) for continuous variables. Differences between groups were
analyzed by analysis of variance and Mantel Haenszel linear-by-linear trend as appropriate.
https://doi.org/10.1371/journal.pone.0244089.t001
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Baseline correlation analysis was repeated for patients belonging to the ORENTRA trial
control group (rs = 0.45, p<0.001, n = 66, S5 Fig) and we found a high degree of agreement
between the methods (S6 Fig), similar to what was shown for the whole study cohort at
baseline.
We performed a multivariate stepwise forward regression analysis, adjusting for the poten-
tial confounding factors recipient age, gender, height, weight, body mass index, renal function,
physical activity, educational level and smoking habits (p<0.10 for inclusion of variables in the
final regression model) at baseline and end of study. The reference biomarker plasma PL
marine n-3FA level was associated with FFQ based marine n-3FA consumption estimates (Std.
β-coeff. 0.24, p = 0.01), as well as recipient age (Std. β-coeff. 0.25, p = 0.01) and smoking habits
(Std. β-coeff. 0.15, p = 0.06) at baseline (n = 132). Together the three variables included in final
Fig 2. Scatterplots of standardized plasma PL marine n-3FA levels and standardized FFQ based marine n-3FA
consumption estimates with regression line at eight weeks post-transplant (n = 132).
https://doi.org/10.1371/journal.pone.0244089.g002
Fig 3. Bland-Altman plot assessing degree of agreement between standardized plasma PL marine n-3FA levels
and standardized FFQ based marine n-3FA consumption estimates at baseline eight weeks post-transplant. We
used standardization of data obtained by the study FFQ and reference biomarker, hence the mean value was set at 0.
The upper and lower limits of agreement were set at 2 standard deviations from the mean. The Bland Altman plot
includes all patients enrolled in the ORENTRA trial (n = 132) at the baseline time-point.
https://doi.org/10.1371/journal.pone.0244089.g003
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regression model explained 23% of the variance in plasma PL marine n-3FA levels. At the end
of study, only FFQ based marine n-3FA consumption estimates (Std. β-coeff. 0.54, p<0.001)
was included in the final regression model, and it explained 29% of the variance in the refer-
ence biomarker.
Correlations between FFQ based marine n-3FA consumption estimates and the reference
biomarker were slightly weaker for fatty fish intake (approach 2, baseline rs = 0.35 and end of
study rs = 0.46) and number of fish servings per month (approach 3, baseline rs = 0.38 and end
of study rs = 0.43) than for total marine n-3FA consumption estimates (approach 1). Correla-
tions with the reference biomarker for individual food items included in the study FFQ are
shown in S7 Fig. The food item cod liver oil showed a low correlation with the reference
Fig 4. Scatterplots of standardized plasma PL marine n-3FA levels and standardized FFQ based marine n-3FA
consumption estimates with regression line at one year post-transplant for patients belonging to the control
group of the ORENTRA trial (n = 64).
https://doi.org/10.1371/journal.pone.0244089.g004
Fig 5. Bland-Altman plot assessing degree of agreement between standardized plasma PL marine n-3FA levels
and standardized FFQ based marine n-3FA consumption estimates at one year post-transplant. We used
standardization of data obtained by the study FFQ and reference biomarker, hence the mean value was set at 0. The
upper and lower limits of agreement were set at 2 standard deviations from the mean. The Bland Altman plot includes
only patients belonging to the control group of the ORENTRA trial (n = 64) at the end of study time-point.
https://doi.org/10.1371/journal.pone.0244089.g005
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biomarker at baseline (rs = 0.21). Marine n-3FA supplementation, including cod liver oil, was
discontinued after enrollment in the ORENTRA trial and consequently intake of cod liver oil
did not influence results at one year post-transplant.
Discussion
The main finding of the present study was that marine n-3FA consumption estimates based on
a new FFQ focused on fish consumption showed a moderate correlation with the reference
biomarker plasma PL marine n-3FA levels at eight weeks post-transplant and a slightly stron-
ger correlation at one year post-transplant. The correlations found in the present study are in
the range of what is regarded as acceptable in FFQ validation studies [22].
Previous FFQs have mainly focused on fatty fish intake, assumed to reflect marine n-3FA
consumption better than total fish intake [23–35]. We hypothesized that a more meticulous
approach using weighted response scales based on EPA and DHA content in fatty and lean
fish, other seafoods and marine n-3FA supplements would provide a more precise estimation
of marine n-3FA consumption. In our cohort, approach 1, which estimated total marine n-
3FA consumption from all the data obtained by the study FFQ, showed a stronger correlation
with the reference biomarker than approach 2 (which only focused on fatty fish intake) and 3
(which used the number of fish servings), suggesting that our hypothesis was correct.
However, the study FFQ only provided slightly stronger correlations than most recent
FFQs focused on fish consumption (Table 2) and the utility of the study FFQ will have to be
confirmed by other studies before it can be used in epidemiological research.
Plasma PL marine n-3FA levels did not differ between baseline and end of study visits for
the majority of patients. This is consistent with previous reports from large Norwegian cohorts
and supports the notion that a single fatty acid measurement may be acceptable for epidemio-
logical studies [3, 19]. However, the association between FFQ based marine n-3FA consump-
tion estimates and the reference biomarker was stronger at end of study than at baseline.
There could be several explanations to this finding. Study participants might have become
more aware of their eating habits due to participation in the ORENTRAL trial and reported
fish consumption more accurately when they completed the FFQ the second time. We found a
Table 2. Summary of selected food frequency questionnaire validation studies published during the last six years, focusing on fish and/or marine fatty acid con-
sumption, using circulating phospholipids or erytrocytes as the reference biomarker.
First author (reference) Published, year n Study population Reference marine fatty acid biomarker Correlation coefficient
Giovannelli J [23] 2014 2630 General population Plasma phospholipid r = 0.39–0.43
Lassale C [24] 2016 198 General population Plasma phospholipid rs = 0.51–0.54
Sluik D [25] 2016 383 General population Plasma phospholipid r = 0.43–0.47
Whitton C [26] 2017 161 General population Plasma phospholipid r = 0.36
Laursen UB [27] 2018 200 General population Plasma phospholipid rs = 0.45
Shen W [28] 2019 108 General population Whole blood phospholipid r = 0.67
Schumacher TL [29] 2016 39 Hyperlipidemia Erythrocyte rs = 0.53–0.62
Allaire J [30] 2015 60 Prostate cancer Erythrocyte rs = 0.59
Brunvoll SH [31] 2018 49 Breast cancer Serum phospholipid r = 0.36–0.53
Lepsch J [32] 2014 248 Pregnant women Serum phospholipid rs = 0.21–0.26
Zhou YB [33] 2017 804 Pregnant women Plasma phospholipid rs = 0.35
Erythrocyte rs = 0.33
Kobayashi M [34] 2017 188 Pregnant women Serum phospholipid rs = 0.33–0.45
Liu MJ [35] 2016 408 Lactating women Plasma phospholipid rs = 0.36
Erythrocyte rs = 0.24
https://doi.org/10.1371/journal.pone.0244089.t002
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lower correlation with the reference biomarker for cod liver oil than for other food items in the
study FFQ at baseline, which likely influenced the results. Some patients with high plasma PL
marine n-3FA levels reported only average marine n-3FA intake according to the study FFQ, all
of whom reported frequent use of cod liver oil. This signals that the study FFQ weighted
response scale for cod liver oil likely underestimated marine n-3FA content, thus the study FFQ
in its current form lacks precision for patients taking daily marine n-3FA supplements. Addi-
tionally, patients with average plasma PL marine n-3 FA levels who reported high levels of
marine n-3FA intake in the FFQ, showed this pattern both at baseline and end of study. This
might be due to social desirability bias and has likely influenced results at both time-points.
Fish intake in Norway is higher than in most other European countries, due to the rich fish-
ing grounds along the Norwegian coastline with easy access to fresh cold-water fish [36].
Plasma PL marine n-3FA levels in the present cohort were relatively high, even for a Norwe-
gian population, signaling a selected population that focuses on healthy eating habits. On the
other hand, plasma PL marine n-3FA levels in the present study were comparable to a previous
large cohort study in Norwegian RTRs, suggesting that the sample was representative of a Nor-
wegian transplant cohort [3]. Confounding factors like socioeconomical class, educational
level, smoking habits and physical activity may influence associations between fish intake and
outcomes in epidemiological research [36]. In this cohort, FFQ based marine n-3FA consump-
tion estimates and plasma PL marine n-3FA level were associated with smoking habits, but not
other life-style factors.
Dietary habits are changing in the Nordic countries, with lower fish consumption in youn-
ger patients, including Norwegian RTRs [3], thus necessitating revision of questions and
response categories for the present study FFQ in future studies. Cod liver oil intake is an old
tradition in Norway [37] and was therefore included as one of the food times in the study FFQ.
This may be omitted in areas where intake of cod liver oil or other marine n-3FA supplements
are uncommon.
Strengths of the present study include a well-described cohort, plasma PL fatty acid analysis
and a study FFQ performed at two time points, which might improve accuracy. The study
FFQ has a simple design, is easy to read and understand and only takes a few minutes to
answer, which is desirable in large epidemiological studies.
There were also several limitations, including limitations by design such as recall bias and
social desirability bias and a relatively small sample size. The study FFQ marine n-3FA con-
sumption estimates were based on the sum of weighted response scales for ten food items, con-
taining questions on how frequent the food items were consumed, but not on portion size.
Thus, the weighted responses used to calculate marine n-3FA intake were based on assump-
tions of standard portion size for each item, constituting a major limitation in the present
study. Moreover, the study FFQ did not contain any questions regarding seasonal variations,
which could be relevant for some of the included food items in a Norwegian cohort. The study
FFQ contains rather detailed questions about fish and seafood intake and response categories
with minor differences (Fig 1). This likely improved precision for patients who are well aware
of their eating habits but could have been challenging for other patients, possibly leading to
random responses. Broader response categories might have produced more reliable data [38].
For patients on marine n-3FA supplements, like cod liver oil, weighted responses for this food
item in the study FFQ likely underestimated supplements as a source of marine n-3FAs.
The questionnaire was designed to estimate marine n-3FA consumption in a Norwegian
transplant cohort. Due to dietary differences between regions and between patient popula-
tions, FFQ validation studies designed for one region or one particular target population may
not apply to other regions or other patient cohorts [22]. In other regions, food items and
weighted response scales should be revised to reflect fish consumption in that region.
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Moreover, adjustment for portion size and seasonal variations can be made to improve FFQ
performance.
In conclusion, marine n-3FA consumption estimates based on our study FFQ showed a
moderate correlation with the reference biomarker plasma PL marine n-3FA levels, with com-
parable performance to previous FFQs. We recommend using fatty acid analysis to ensure
objective measurement of marine n-3FA consumption in clinical trials, but our FFQ might be
useful in epidemiological studies where resources are limited.
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S1 Fig. Study food frequency questionnaire focusing on food items containing marine n-3
fatty acids (Norwegian version). The study subjects responded to the question “During a typi-
cal month, how often do you eat these food items?” using one of six response alternatives for
each of the ten food item categories.
(PDF)
S2 Fig. Study food frequency questionnaire focusing on food items containing marine n-3
fatty acids (investigator’s scoring sheet version in English). The study subjects responded to
the question “During a typical month, how often do you eat these food items?” using one of six
response alternatives for each of the ten food item categories. Based on EPA and DHA content
in the meat of various fish and other seafoods presented in the US Department of Agriculture
Food Composition Database and assuming a standard portion size for dinner and bread
spread, every potential response was given a weight (shown inside boxes). Total intake of
marine n-3 fatty acids per month was calculated as the sum of the ten weighted responses in
grams.
(PDF)
S3 Fig. Study food frequency questionnaire focusing on food items containing marine n-3
fatty acids (investigator’s scoring sheet version in English comprising fatty fish items
only). The study subjects responded to the question “During a typical month, how often do
you eat these food items?” using one out of six response alternatives for each food item catego-
ries. Based on EPA and DHA content in the meat of various fish and other seafoods presented
in the US Department of Agriculture Food Composition Database and assuming a standard
portion size for dinner and bread spread, every potential response was given a weight (shown
inside boxes). Total intake of marine n-3 fatty acids per month was calculated as the sum of
the weighted responses in grams, which for fatty fish intake comprised the four items shown.
(PDF)
S4 Fig. Study food frequency questionnaire focusing on food items containing marine n-3
fatty acids (investigator’s scoring sheet version in English comprising fish servings per
month). The study subjects responded to the question “During a typical month, how often do
you eat these food items?” using one out of six response alternatives for each of the ten food
item categories. Servings of fish per month was calculated as the sum of the ten responses,
using the center value for each response category as shown.
(PDF)
S5 Fig. Scatterplots of standardized plasma marine n-3FA levels and standardized FFQ
based marine n-3FA consumption estimates with regression lines at baseline eight weeks
post-transplant for patients belonging to the control group of the ORENTRA trial
(n = 66).
(TIF)
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S6 Fig. Bland-Altman plot assessing degree of agreement between standardized plasma
marine n-3FA levels and standardized FFQ based marine n-3FA consumption estimates at
baseline eight weeks post-transplant for patients belonging to the control group of the
ORENTRA trial (n = 66).
(TIF)
S7 Fig. Correlation matrix presenting Spearman’s correlation coefficients at eight weeks
(baseline visit) after renal transplantation for the whole study population (n = 132) and
one year post-transplant (end of study visit) for patients belonging to the control group of
the ORENTRA trial (n = 64).
(TIF)
S1 File. Supporting information. Includes information regarding “Patient screening and
recruitment in the ORENTRA trial”, “Fatty acid analysis”, “Sample Size and Power Calcula-
tion” and “Development of the study Food Frequency Questionnaire”.
(DOCX)
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